These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 1691412)

  • 21. Calcium antagonists and the diabetic hypertensive patient.
    Parving HH; Rossing P
    Am J Kidney Dis; 1993 Jun; 21(6 Suppl 3):47-52. PubMed ID: 8503435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperfiltration and diabetic nephropathy: is it the beginning? Or is it the end?
    Castellino P; Shohat J; DeFronzo RA
    Semin Nephrol; 1990 May; 10(3):228-41. PubMed ID: 2190280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic implications of converting-enzyme inhibitors in renal disease.
    Anderson S; Brenner BM
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):81-7. PubMed ID: 3037894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Renal complications of diabetes].
    Tielemans C
    Rev Med Brux; 1995; 16(4):258-61. PubMed ID: 7481238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ace inhibition in renal disease: risks and benefits.
    Campanacci L; Fabris B; Fischetti F; Bardelli M; Vran F; Carretta R
    Clin Exp Hypertens; 1993; 15 Suppl 1():173-86. PubMed ID: 8513308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypertension and chronic renal failure: the use of ACE inhibitors.
    Porush JG
    Am J Kidney Dis; 1998 Jan; 31(1):177-84. PubMed ID: 9428471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of angiotensin-converting-enzyme inhibition in patients with renal disease.
    Manley HJ
    Am J Health Syst Pharm; 2000 Oct; 57 Suppl 1():S12-8. PubMed ID: 11030018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
    Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
    Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypertension with co-existing renal disease.
    Bauer JH; Reams GP
    J Hum Hypertens; 1990 Dec; 4 Suppl 5():27-34. PubMed ID: 2090835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions.
    Keane WF; Anderson S; Aurell M; de Zeeuw D; Narins RG; Povar G
    Ann Intern Med; 1989 Sep; 111(6):503-16. PubMed ID: 2491421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Approach to the treatment of diabetic nephropathy.
    Burke JM
    Pharm Pract Manag Q; 1997 Jul; 17(2):26-35. PubMed ID: 10168175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Losartan in patients with renal insufficiency.
    de Zeeuw D; Gansevoort RT; de Jong PE
    Can J Cardiol; 1995 Aug; 11 Suppl F():41F-44F. PubMed ID: 7664217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical use of angiotensin-converting enzyme inhibitors in patients with renal impairment.
    Elliott HL
    Blood Press Suppl; 1994; 2():31-4. PubMed ID: 8061843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACE inhibitors in renal disease.
    Bauer JH; Reams GP
    Clin Cardiol; 1991 Aug; 14(8 Suppl 4):IV38-43; discussion IV51-5. PubMed ID: 1893641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.
    Baba T; Neugebauer S; Watanabe T
    Drugs; 1997 Aug; 54(2):197-234. PubMed ID: 9257079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin-converting enzyme inhibitors in the treatment of diabetic glomerulopathy.
    Myers BD; Meyer TW
    Nephron; 1990; 55 Suppl 1():27-9. PubMed ID: 2345590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin converting enzyme inhibitors in perspective: an update.
    Burrell LM; Johnston CI
    Aust Fam Physician; 1993 Jul; 22(7):1243-7, 1251, 1255. PubMed ID: 8373316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microvascular hemodynamics in hypertension and diabetes.
    Tooke JE; Sandeman DD; Shore AC
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S51-3. PubMed ID: 1725043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.